Hepatitis C virus in Asia: utility values based on the Short Form-36 questionnaire

References

• Asian Pacific Association for the Study of the Liver (APASL) Hepatitis C Working Party. Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J. Gastroenterol. Hepatol. 22, 615–622 (2007).
   PubMed Web of Science ®Google Scholar
• Sievert W, Altraif I, Razavi HA et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int. 31(Suppl. 2), 61–80 (2011).
   PubMed Web of Science ®Google Scholar
• Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 27(1), 209–212 (1998).
   PubMed Web of Science ®Google Scholar
• Bonkovsky HL, Woolley JM. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group. Hepatology 29(1), 264–270 (1999).
   PubMed Web of Science ®Google Scholar
• Ware JE, Snow KK, Kosinski M et al. SF-36 Health Survey: Manual & Interpretation Guide. The Health Institute, New England Medical Centre, MA, USA (1993).
   Google Scholar
• Ware JE Jr, Bayliss MS, Mannocchia M, Davis GL. Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. The Interventional Therapy Group. Hepatology 30(2), 550–555 (1999).
   PubMed Web of Science ®Google Scholar
• The EuroQol group. EuroQol – a new facility for the measurement of health related quality of life. Health Policy 16, 199–208 (1990).
   PubMed Web of Science ®Google Scholar
• Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J. Health Econ. 21(2), 271–292 (2002).
   PubMed Web of Science ®Google Scholar
• Chang CC, Chen TY, Chen TH et al. [The analysis of different course of treatment with pegylated interferon plus ribavirin for genotype 1 hepatitis C virus.] Chung. Shan. Med. J. 21, 381–396 (2010).
   Google Scholar
• Ma YY, Ha N, Yang XJ. [Pharmacoeconomic evaluation of 2 therapeutic schemes for chronic hepatitis C.] China Pharmacy 21, 1642–1645 (2010).
   Google Scholar
• Brazier JE, Yang Y, Tsuchiya A, Rowen DL. A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. Eur. J. Health Econ. 11(2), 215–225 (2010).
   PubMed Web of Science ®Google Scholar
• Brady CW, Muir AJ. The impact of race and ethnicity on the treatment of hepatitis C disease. Curr. Hepat. Rep. 5, 79–85 (2006).
   Google Scholar
• Tanaka E, Crawford B, Yeung CK et al. PP12-018 Hepatitis C in Asia: prevalence and complications, The 22nd Conference of the Asian Pacific Association for the Study of the Liver. Hepatol. Int. 6, 157 (2012).
   Google Scholar
• Lee YK, Nam HS, Chuang LH et al. South Korean time trade-off values for EQ-5D health states: modeling with observed values for 101 health states. Value Health 12(8), 1187–1193 (2009).
   PubMed Web of Science ®Google Scholar
• Ara R, Brazier J. Deriving an algorithm to convert the eight mean SF-36 dimension scores into a mean EQ-5D preference-based score from published studies (where patient level data are not available). Value Health 11(7), 1131–1143 (2008).
   PubMed Web of Science ®Google Scholar
• Ara R, Brazier J. Predicting the short form-6D preference-based index using the eight mean short form-36 health dimension scores: estimating preference-based health-related utilities when patient level data are not available. Value Health 12(2), 346–353 (2009).
   PubMed Web of Science ®Google Scholar
• Rowen D, Brazier J, Roberts J. Mapping SF-36 onto the EQ-5D index: how reliable is the relationship? Health Qual. Life Outcomes 7, 27 (2009).
   PubMed Web of Science ®Google Scholar
• Lin WA, Tarn YH, Tang SL. Cost-utility analysis of different peg-interferon α-2b plus ribavirin treatment strategies as initial therapy for naive Chinese patients with chronic hepatitis C. Aliment. Pharmacol. Ther. 24(10), 1483–1493 (2006).
   PubMed Web of Science ®Google Scholar
• Siebert U, Sroczynski G, Rossol S et al.; German Hepatitis C Model (GEHMO) Group; International Hepatitis Interventional Therapy (IHIT) Group. Cost effectiveness of peginterferon α-2b plus ribavirin versus interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 52(3), 425–432 (2003).
   PubMed Web of Science ®Google Scholar
• Sun B, Yang X, Wu LY. [A survey of status quo of anxiety in chronic hepatitis C patients]. Chin. Nurs. Res. 19, 2097–2099 (2005).
   Google Scholar
• Zhang GQ, Zhang Q, Kong LY et al. [Measuring and assessing the quality of life of patients with chronic hepatitis C]. Med. Innovation Res. 4, 19 (2007).
   Google Scholar
• Jin CH, Yao GB. [Investigation of the health related quality of life in patients with chronic hepatitis C]. Chin. J. Infect. Dis. 2, 36–40 (2003).
   Google Scholar
• Guo F, Zhang L, Sun DG et al. [Evaluation of health related quality of life in chronic hepatitis women patients]. Chin. J. Hepatol. 12, 156–159 (2004).
   PubMedGoogle Scholar
• Kang SC, Hwang SJ, Lee SH, Chang FY, Lee SD. Health-related quality of life and impact of antiviral treatment in Chinese patients with chronic hepatitis C in Taiwan. World J. Gastroenterol. 11(47), 7494–7498 (2005).
   PubMedGoogle Scholar
• Park CG, Park SY, Kim ES et al. [Assessment of quality of life and associated factors in patients with chronic viral liver disease]. Korean J. Hepatol. 9, 212–221 (2003).
   Google Scholar
• Chang SC, Ko WS, Wu SS, Peng CY, Yang SS. Factors associated with quality of life in chronic hepatitis C patients who received interferon plus ribavirin therapy. J. Formos. Med. Assoc. 107(6), 454–462 (2008).
   PubMedGoogle Scholar
• Wang JH, Zhang ZN, Chen BY. [The effect of psychological intervention to quality of life among CHC patients]. Chin. J. Clin. Rehabil. 9, 36–37 (2005).
   Google Scholar
• Walters SJ, Brazier JE. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual. Life Res. 14(6), 1523–1532 (2005).
   PubMed Web of Science ®Google Scholar
• Lam ETP, Lam CLK, Lai CL, Yuen MF, Fong DFT, So TMK. Health-related quality of life of Southern Chinese with chronic hepatitis B infection. Health Qual. Life Outcomes 7, 52 (2009).
   PubMed Web of Science ®Google Scholar
• Thein HH, Krahn M, Kaldor JM, Dore GJ. Estimation of utilities for chronic hepatitis C from SF-36 scores. Am. J. Gastroenterol. 100(3), 643–651 (2005).
   PubMed Web of Science ®Google Scholar
• McLernon DJ, Dillon J, Donnan PT. Health-state utilities in liver disease: a systematic review. Med. Decis. Making 28(4), 582–592 (2008).
   PubMed Web of Science ®Google Scholar
• Grieve R, Grishchenko M, Cairns J. SF-6D versus EQ-5D: reasons for differences in utility scores and impact on reported cost-utility. Eur. J. Health Econ. 10(1), 15–23 (2009).
   PubMed Web of Science ®Google Scholar
• Tarn YH, Hu S, Kamae I et al. Health-care systems and pharmacoeconomic research in Asia–Pacific region. Value Health 11(Suppl. 1), S137–S155 (2008).
   PubMed Web of Science ®Google Scholar
• Yang BM. The future of health technology assessment in healthcare decision making in Asia. Pharmacoeconomics 27(11), 891–901 (2009).
   PubMed Web of Science ®Google Scholar
• Jirawattanapisal T, Kingkaew P, Lee TJ, Yang MC. Evidence-based decision-making in Asia–Pacific with rapidly changing health-care systems: Thailand, South Korea, and Taiwan. Value Health 12(Suppl. 3), S4–S11 (2009).
   PubMedGoogle Scholar